GBIM:OTCMKTS
GlobeImmune Inc
0,00010 US$
0,00%
(0,00) 1 d
29 sept, 15:48:52 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de GBIM...
Cap. burs.
580,00
Vol. medio
1,74 mil
Volumen
0,00
Máximo en 52 sem.
0,04 US$
Mínimo en 52 sem.
0,00 US$
Acciones en circulación
5,75 M
N.º de empleados
22
Cap. burs.
580,00
Vol. medio
1,74 mil
Volumen
0,00
Máximo en 52 sem.
0,04 US$
Mínimo en 52 sem.
0,00 US$
Acciones en circulación
5,75 M
N.º de empleados
22
Noticias
De fuentes web y partners de noticias
FXStreet
·
hace 6 minutos
Las ganancias de los futuros del Dow Jones antes de los datos del IPP y las ventas minoristas de EE.UU.
El Ecosistema Startup
·
hace 23 horas
S&P 500: IA impulsa 34% de crecimiento en ganancias
MarketScreener España
·
hace 4 horas
El S&P 500 retrocedió ligeramente tras el cierre de la Bolsa de Estocolmo el miércoles
Perfil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Acerca de GlobeImmune Inc
CEO-
Empleados22
Fundación1 ene 1995
SedeLouisville, Colorado, Estados Unidos
Sector-
Sitio webglobeimmune.com